Key result
Long-term ticagrelor or prasugrel shows no benefit over clopidogrel for 3-year major cardiovascular events in post-PCI AMI.
Why the study?
The study was designed to compare long-term clinical outcomes of DAPT with clopidogrel versus DAPT with ticagrelor or prasugrel in patients with AMI undergoing coronary intervention.
Does long-term DAPT with ticagrelor or prasugrel improve clinical outcomes compared to clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention?
Cohort (n=4,696)
Yes
Does long-term DAPT with ticagrelor or prasugrel improve clinical outcomes compared to clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In East Asian patients with AMI undergoing PCI, long-term DAPT (>24 months) with ticagrelor or prasugrel did not significantly reduce 3-year net adverse clinical events compared to clopidogrel, suggesting DAPT type should be individualized.
BACKGROUND AND OBJECTIVES: To compare the long-term clinical outcomes of dual antiplatelet therapy (DAPT) with clopidogrel and DAPT with ticagrelor or prasugrel in patients with acute myocardial infarction (AMI) who underwent coronary intervention. METHODS: Between November 2011 and December 2015, a total of 13,104 patients with AMI were enrolled in the Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) registry. Among them, 4,696 patients who received DAPT for more than 24 months were categorized into two groups: the clopidogrel group (n = 4,053) and ticagrelor or prasugrel group (n = 643). Propensity score matching (PSM) was used to reduce the bias due to confounding variables. Following PSM, the impacts of P2Y12 inhibitors on the clinical outcomes in both groups were compared during a 36-month clinical follow-up period. RESULTS: There were no significant differences in clinical outcomes in terms of cardiac death (7.1% vs. 9.7%, p = 0.101), stroke (1.4% vs. 1.0%, p = 0.436), major bleeding (0.5% vs. 0.8%, p = 0.478), major adverse cardiac events (MACE) (21.6% vs. 20.5%, p = 0.626), and net adverse cardiac event (NACE) (22.1% vs. 21.3%, p = 0.731) between the groups. The ticagrelor or prasugrel group had a lower incidence of recurrent percutaneous coronary intervention (PCI) (12.2% vs. 7.6%, p = 0.006) than the clopidogrel group. However, no differences were observed in the cumulative incidences of 3-year NACE between the ticagrelor or prasugrel and clopidogrel groups. CONCLUSIONS: Cumulative incidences of long-term NACE did not differ between the two groups. Therefore, the type and duration of DAPT should be customized for each patient with AMI.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) conducted a cohort in Acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) (n=4,696). Ticagrelor or prasugrel vs. Clopidogrel 75 mg once daily was evaluated on Cumulative incidence of major adverse cardiac events (MACE) during 3 years of clinical follow-up (p=0.626). In patients with acute myocardial infarction who underwent percutaneous coronary intervention, long-term dual antiplatelet therapy with ticagrelor or prasugrel did not reduce the 3-year incidence of major adverse cardiac events compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: